Acute Myelogenous Leukemia with a t(2;17;4)(p13;q21;p16) Aberration: Effective Treatment with All-Trans Retinoic Acid and Granulocyte Colony-Stimulating Factor

Shigetaka SHIMODAIRA; Kiyoshi KITANO; Yoshio NISHIZAWA; Naoaki ICHIKAWA; Fumihiro ISHIDA; Ichiro KAMINO; Hiroko MATSUI; Kendo KIYOSAWA

doi:10.2169/internalmedicine.38.150

Acute Myelogenous Leukemia with a t(2;17;4)(p13;q21;p16) Aberration: Effective Treatment with All-Trans Retinoic Acid and Granulocyte Colony-Stimulating Factor

Shigetaka SHIMODAIRA, Kiyoshi KITANO, Yoshio NISHIZAWA, Naoaki ICHIKAWA, Fumihiro ISHIDA, Ichiro KAMINO, Hiroko MATSUI, Kendo KIYOSAWA

Author information

Keywords: acute myelogenous leukemia (M2), chromosomal aberration, differentiation therapy, retinoic acid receptor α

JOURNAL FREE ACCESS

1999 Volume 38 Issue 2 Pages 150-154

DOI https://doi.org/10.2169/internalmedicine.38.150

Details

Abstract

The efficacy of all-trans retinoic acid (ATRA) in patients with acute promyeiocytic leukemia (APL) has been well documented. However, ATRA is not as effective against other types of acute myelogenous leukemia (AML) or myelodysplastic syndromes. We present a patient with AML (FAB: M2) associated with a t(2;17;4)(p13;q21;p16) chromosomal defect in which the 17q21 breakpoint was not within the retinoic acid receptor α locus which is typically rearranged in APL. This patient was successfully treated with ATRA and granulocyte colony-stimulating factor and improvement of hematological parameters lasted for 19 months without the use of cytotoxic agents.
(Internal Medicine 38: 150-154, 1999)

Corresponding author

Register with J-STAGE for free!